Eureka Genomics (EG) develops Next Generation Sequencing (NGS)-based assays and diagnostics. The EG technology platform uses proprietary software, algorithms and database to build bioinformatics applications and services, focusing NGS assay design and translating data into useful, comprehensive and powerful analysis of NGS data. As a leader in advanced bioinformatics analysis of NGS data, EG leverages this expertise building the backbone of their novel next-gen genotyping (NGG). The NGG for clinical, animal and crop applications enable highly-efficient, targeted sequencing and flexible exploration of relevant genetic markers (SNPs, CNV, gene expression, methylation) in a massively parallel, platform agnostic technology. In addition, the company is currently developing molecular diagnostics for the identification of colorectal cancer and pre-term birth and exploring other opportunities for diagnostic development.
The EG initial core bioinformatics technology was developed at the University of Houston Bioinformatics lab (2002-2009). Since then, EG has extended the bioinformatics capabilities of the platform to encompass storage, manipulation and analysis of high throughput sequencing data, opening the door for commercialization of NGS services related to de novo assembly, miRNA/RNA analysis, identification of foreign genomic material, shotgun/16S metagenomic characterization and rare variant detection. With the addition of NGS-based, proprietary next-gen genotyping (NGG) in 2012, EG seeks to address research needs in animal health, plant science and other AgBio applications, as well as moving into the therapeutic and clinical testing markets as a service provider and research partner. EG has been providing NGS and bioinformatics services to US National Labs, the Department of Homeland Security, the Federal Bureau of Investigation, the US Armed Forces, the US Department of Agriculture and various universities, research centers and pharmaceutical/biotechnology companies around the world since 2008.